Predictive Capacity of 3 Comorbidity Indices in Estimating Survival Endpoints in Women with Early-Stage Endometrial Carcinoma

International Journal of Gynecological Cancer

Volumn 26, Issue 8, 2016, Pages 1455-1460

  Al Feghali, Karine A ^a   Robbins, Jared R ^a   Mahan, Meredith ^a   Burmeister, Charlotte ^a   Khan, Nadia T ^a   Rasool, Nabila ^a   Munkarah, Adnan ^a   Elshaikh, Mohamed A ^a  

^a HENRY FORD HOSPITAL   (United States)

Author keywords

ACE 27; Age adjusted; Charlson Comorbidity Index; Comorbidity; Endometrial cancer; Prognosis; Survival

Indexed keywords

ADULT COMORBIDITY EVALUATION 27; AGE ADJUSTED CHARLSON COMORBIDITY INDEX; CANCER GRADING; CANCER PATIENT; CANCER SURVIVAL; CAUSE OF DEATH; CHARLSON COMORBIDITY INDEX; COMORBIDITY ASSESSMENT; CONFERENCE PAPER; DISEASE SPECIFIC SURVIVAL; EARLY CANCER; ENDOMETRIUM CARCINOMA; FEMALE; HUMAN; LYMPH VESSEL METASTASIS; MAJOR CLINICAL STUDY; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGNOSTIC ASSESSMENT; RECURRENCE FREE SURVIVAL; RETROSPECTIVE STUDY; UTERUS; ADULT; AGED; BIOASSAY; CANCER STAGING; COMORBIDITY; ENDOMETRIOID CARCINOMA; ENDOMETRIUM TUMOR; HYSTERECTOMY; MIDDLE AGED; MORTALITY; PATHOLOGY; PROPORTIONAL HAZARDS MODEL; RANDOMIZED CONTROLLED TRIAL (TOPIC); SEVERITY OF ILLNESS INDEX; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; CARCINOMA, ENDOMETRIOID; COMORBIDITY; ENDOMETRIAL NEOPLASMS; ENDPOINT DETERMINATION; FEMALE; HUMANS; HYSTERECTOMY; MIDDLE AGED; NEOPLASM STAGING; PROPORTIONAL HAZARDS MODELS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RETROSPECTIVE STUDIES; SEVERITY OF ILLNESS INDEX;

EID: 84990038762     PISSN: 1048891X     EISSN: 15251438     Source Type: Journal    
DOI: 10.1097/IGC.0000000000000802     Document Type: Conference Paper

References (35)

1. Fader AN, Arriba LN, Frasure HE, et al. Endometrial cancer and obesity: epidemiology, biomarkers, prevention and survivorship. Gynecol Oncol. 2009;114:121-127.
2. Folsom AR, Anderson KE, Sweeney C, et al. Diabetes as a risk factor for death following endometrial cancer. Gynecol Oncol. 2004;94:740-745.
3. Chia VM, Newcomb PA, Trentham-Dietz A, et al. Obesity, diabetes, and other factors in relation to survival after endometrial cancer diagnosis. Int J Gynecol Cancer. 2007; 17:441-446.
4. Ward KK, Shah NR, Saenz CC, et al. Cardiovascular disease is the leading cause of death among endometrial cancer patients. Gynecol Oncol. 2012;126:176-179.
5. Robbins JR, Gayar OH, Zaki M, et al. Impact of age-adjusted Charlson comorbidity score on outcomes for patients with early-stage endometrial cancer. Gynecol Oncol. 2013;131: 593-597.
6. Calle EE, Rodriguez C,Walker-Thurmond K, et al. Overweight, obesity, and mortality from cancer in a prospectively studied cohort of U.S. adults. N Engl J Med. 2003;348:1625-1638.
7. von Gruenigen VE, Tian C, Frasure H, et al. Treatment effects, disease recurrence, and survival in obese women with early endometrial carcinoma: a Gynecologic Oncology Group study. Cancer. 2006;107:2786-2791.
8. Keys HM, Roberts JA, Brunetto VL, et al. A phase III trial of surgery with or without adjunctive external pelvic radiation therapy in intermediate risk endometrial adenocarcinoma: a Gynecologic Oncology Group study. Gynecol Oncol. 2004; 92:744-751.
9. Creutzberg CL, van Putten WL, Koper PC, et al. Surgery and postoperative radiotherapy versus surgery alone for patients with stage-1 endometrial carcinoma: multicentre randomised trial. PORTEC Study Group. Post Operative Radiation Therapy in Endometrial Carcinoma. Lancet. 2000;355:1404-1411.
10. Piccirillo JF, Tierney RM, Costas I, et al. Prognostic importance of comorbidity in a hospital-based cancer registry. JAMA. 2004;291:2441-2447.
11. Janssen-Heijnen ML, Maas HA, Houterman S, et al. Comorbidity in older surgical cancer patients: influence on patient care and outcome. Eur J Cancer. 2007;43:2179-2193.
12. Yancik R, Wesley MN, Ries LA, et al. Effect of age and comorbidity in postmenopausal breast cancer patients aged 55 years and older. JAMA. 2001;285:885-892.
13. Charlson ME, Pompei P, Ales KL, et al. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis. 1987;40:373-383.
14. Koppie TM, Serio AM, Vickers AJ, et al. Age-adjusted Charlson comorbidity score is associated with treatment decisions and clinical outcomes for patients undergoing radical cystectomy for bladder cancer. Cancer. 2008;112:2384-2392.
15. Ouellette JR, Small DG, Termuhlen PM. Evaluation of Charlson-Age Comorbidity Index as predictor of morbidity and mortality in patients with colorectal carcinoma. J Gastrointest Surg. 2004;8:1061-1067.
16. Charlson M, Szatrowski TP, Peterson J, et al. Validation of a combined comorbidity index. J Clin Epidemiol. 1994;47: 1245-1251.
17. Piccirillo JF. Importance of comorbidity in head and neck cancer. Laryngoscope. 2000;110:593-602.
18. Piccirillo JF, Costas I, Claybour P, et al. Development of a comorbidity index using physician claims data. J Registry Manage. 2003;30:1258-1267.
19. Kaplan MH, Feinstein AR. The importance of classifying initial co-morbidity in evaluating the outcome of diabetes mellitus. J Chronic Dis. 1974;27:387-404.
20. Radiation Therapy Oncology Group (RTOG): RTOG 0815 Protocol Information. Available at: https://www.rtog.org/ ClinicalTrials/ProtocolTable/StudyDetails.aspx?study=0815. Accessed February 07, 2016.
21. Suidan RS, Leitao MM Jr, Zivanovic O, et al. Predictive value of the Age-Adjusted Charlson Comorbidity Index on perioperative complications and survival in patients undergoing primary debulking surgery for advanced epithelial ovarian cancer. Gynecol Oncol. 2015;138:246-251.
22. Datema FR, Ferrier MB, van der Schroeff MP, et al. Impact of comorbidity on short-term mortality and overall survival of head and neck cancer patients. Head Neck. 2010;32:728-736.
23. Feinstein AR. The pre-therapeutic classification of co-morbidity in chronic disease. J Chronic Dis. 1970;23:455-468.
24. Elshaikh MA, Vance S, Kamal M, et al. Influence of comorbidity on the risk of death: a single institution study of 1132 women with early-stage uterine cancer. Am J Clin Oncol. 2014;12:[Epub ahead of print].
25. Hines RB, Chatla C, Bumpers HL, et al. Predictive capacity of three comorbidity indices in estimating mortality after surgery for colon cancer. J Clin Oncol. 2009;27:4339-4345.
26. Guo R, Chen XZ, Chen L, et al. Comorbidity predicts poor prognosis in nasopharyngeal carcinoma: development and validation of a predictive score model. Radiother Oncol. 2015;114:249-256.
27. de Groot V, Beckerman H, Lankhorst GJ, et al. How to measure comorbidity. a critical review of available methods. J Clin Epidemiol. 2003;56:221-229.
28. Extermann M. Measuring comorbidity in older cancer patients. Eur J Cancer. 2000;36:453-471.
29. Mayr R, May M, Martini T, et al. Predictive capacity of four comorbidity indices estimating perioperative mortality after radical cystectomy for urothelial carcinoma of the bladder. BJU Int. 2012;110:E222YE227.
30. Klabunde CN, Potosky AL, Legler JM, et al. Development of a comorbidity index using physician claims data. J Clin Epidemiol. 2000;53:1258-1267.
31. Elixhauser A, Steiner C, Harris DR, et al. Comorbidity measures for use with administrative data. Med Care. 1998;36:8-27.
32. Chia SK, Speers CH, D'Yachkova Y, et al. The impact of new chemotherapeutic and hormone agents on survival in a population-based cohort of women with metastatic breast cancer. Cancer. 2007;110:973-979.
33. Wolters U, Wolf T, Stü tzer H, et al. ASA classification and perioperative variables as predictors of postoperative outcome. Br J Anaesth. 1996;77:217-222.
34. Havlik RJ, Yancik R, Long S, et al. The National Institute on Aging and the National Cancer Institute SEER collaborative study on comorbidity and early diagnosis of cancer in the elderly. Cancer. 1994;74:2101-2106.
35. Kieszak SM, Flanders WD, Kosinski AS, et al. A comparison of the Charlson comorbidity index derived from medical record data and administrative billing data. J Clin Epidemiol. 1999;52:137-142.